Skip to content
Screener

Exelixis EXEL Business Segments — Selling, general, and administrative

Similar metrics at other companies

Neurocrine Biosciences logo
NBIXReportable Segment — Selling, general, and administrative
$318.5M+15.2%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Selling, general, and administrative
$82.01M+18.8%
Novavax logo
NVAXReportable Segment — Selling, general, and administrative
$26.67M-38.9%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Selling, general, and administrative
$23.3M+7.2%
Five Point Holdings, Inc. logo
FPHTotal Operating Segments — Selling, general, and administrative
$6.19M+1.5%
Micron Technology logo
MUAEBU — Selling, general, and administrative
$58M+28.9%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept exel:SellingGeneralAndAdministrativeExpenseExcludingSeparateAccounts.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of goods sold20,65719,47040,61038,642
Drug discovery18,25221,35737,72839,610
Development150,522134,159286,237287,376
Selling, general, and administrative127,413112,931250,283233,706
Other segment items(1)63,37866,718124,616124,134
Interest income(14,210)(16,789)(30,337)(35,865)
Provision for income taxes50,62845,567107,84891,641
Segment and consolidated net income$212,050$184,848$422,517$344,464

Item 1. Financial Statements.

FAQ

What is Exelixis's business segments — selling, general, and administrative?
Exelixis (EXEL) reported business segments — selling, general, and administrative of $127.41M in Q2 2026.
How has Exelixis's business segments — selling, general, and administrative changed year-over-year?
Exelixis's business segments — selling, general, and administrative increased by 12.8% year-over-year, from $112.93M to $127.41M.
What is the long-term trend for Exelixis's business segments — selling, general, and administrative?
Over 3 years (2022 to 2025), Exelixis's business segments — selling, general, and administrative has grown at a 3.9% compound annual growth rate (CAGR), from $397.63M to $446.54M.
What does business segments — selling, general, and administrative mean?
Includes the costs of marketing, sales force operations, and general corporate overhead required to support the business. This covers the commercial infrastructure needed to promote and distribute products to healthcare providers.

Ask your AI about Exelixis's business segments — selling, general, and administrative.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude